00:25 , Sep 13, 2013 |  BC Extra  |  Politics & Policy

NIH rare disease program selects third round of projects

NIH selected four preclinical Eli Lilly and Co. (NYSE:LLY) to treat hypoparathyroidism and a project from Beth Israel Deaconess Medical Center to use rapamycin to treat hypertrophic cardiomyopathy in Leopard syndrome, which is caused by...
07:00 , Sep 29, 2008 |  BioCentury  |  Product Development

Ophthalmic deals

Ophthalmic deals Date Companies Value [upfront; milestones/royalties] Description Sep 08 Acucela/Otsuka (Tokyo:4768) [$5M; up to $258M] Partner to develop a pair of compounds for ophthalmic indications: Acucela's ACU-4429 for dry age-related macular degeneration (AMD) and...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Company News

Bikam Inc., Dalton Chemical Laboratories Inc. deal

Dalton will use its medicinal chemistry technology to discover several new classes of compounds against undisclosed Bikam targets for ophthalmologic indications. Bikam will use its biological assays and delivery methodologies to further develop the compounds....